
Opinion|Videos|October 6, 2023
EMERALD Trial: Elacestrant for ER+/HER2- Metastatic Breast Cancer
Author(s)Rebecca A. Shatsky, MD
A review of results from the EMERALD trial investigating elacestrant in patients with ESR1-mutated metastatic breast cancer.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
3
HRT Shows No Adverse Effect on Breast Cancer Risk in Patients With BRCA Variant
4
Imlunestrant Regimens Sustain Efficacy Benefit in ER+/HER2– Breast Cancer
5







































